{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:10:55Z","timestamp":1773004255492,"version":"3.50.1"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,25]]},"DOI":"10.18632\/oncotarget.17540","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T11:19:47Z","timestamp":1493551187000},"page":"49264-49274","source":"Crossref","is-referenced-by-count":6,"title":["Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium"],"prefix":"10.18632","volume":"8","author":[{"given":"Markus","family":"Wallner","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"},{"name":"Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, 19140 PA, United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir","family":"Khafaga","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewald","family":"Kolesnik","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aris","family":"Vafiadis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerold","family":"Schwantzer","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah M.","family":"Eaton","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, 19140 PA, United States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pero","family":"Curcic","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"K\u00f6stenberger","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Knez","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Rainer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pichler","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"},{"name":"Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charit\u00e9 University Medicine, Berlin, 13353 Berlin, Germany"},{"name":"Department of Internal Medicine and Cardiology, German Heart Center, Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Von Lewinski","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,4,30]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Jemal","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Berenguer","year":"2009","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2016.05.011","article-title":"Trends in the Incidence of Fatal Prostate Cancer in the United States by Race","volume":"71","author":"Cook","year":"2017","journal-title":"Eur Urol"},{"key":"4","volume-title":"Cancer Stat Facts: Prostate Cancer","author":"Strategies and advances in surgical treatment of breast cancer","year":"2017"},{"key":"5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Rouviere","year":"2017","journal-title":"Eur Urol"},{"key":"6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"D'Amico","year":"2009","journal-title":"JAMA"},{"key":"7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Smith","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Garcia Rodriguez","year":"2011","journal-title":"Drug Saf"},{"key":"9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.urology.2016.06.024","article-title":"Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study","volume":"96","author":"Lay","year":"2016","journal-title":"Urology"},{"key":"10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Heidenreich","year":"2016","journal-title":"Lancet Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/eurheartj\/ehr026","article-title":"Cardiac inotropes: current agents and future directions","volume":"32","author":"Teerlink","year":"2011","journal-title":"Eur Heart J"},{"key":"12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11897-010-0021-9","article-title":"Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?","volume":"7","author":"Gheorghiade","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"13","first-page":"141","article-title":"Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output","volume":"12","author":"Ferrari","year":"2011","journal-title":"Discov Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10741-009-9136-z","article-title":"Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?","volume":"14","author":"Gheorghiade","year":"2009","journal-title":"Heart Fail Rev"},{"key":"15","doi-asserted-by":"publisher","first-page":"41A","DOI":"10.1016\/j.amjcard.2006.09.005","article-title":"Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure","volume":"99","author":"Gheorghiade","year":"2007","journal-title":"Am J Cardiol"},{"key":"16","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.jacc.2008.03.015","article-title":"Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure","volume":"51","author":"Sabbah","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"17","doi-asserted-by":"publisher","first-page":"24415","DOI":"10.18632\/oncotarget.8329","article-title":"Functional characterization and anti-cancer action of the clinical phase II cardiac Na+\/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor","volume":"7","author":"Stournaras","year":"2016","journal-title":"Oncotarget"},{"key":"18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/1389450115666140908125025","article-title":"Na+\/K+ ATPase inhibitors in cancer","volume":"15","author":"Stournaras","year":"2014","journal-title":"Curr Drug Targets"},{"key":"19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/pros.22733","article-title":"Is digoxin use for cardiovascular disease associated with risk of prostate cancer?","volume":"74","author":"Stanford","year":"2014","journal-title":"Prostate"},{"key":"20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2174\/18715206113136660338","article-title":"Steroidal cardiac Na+\/K+ ATPase inhibitors exhibit strong anti-cancer potential in vitro and in prostate and lung cancer xenografts in vivo","volume":"14","author":"Stournaras","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/aje\/kwi203","article-title":"Statins and prostate cancer risk: a case-control study","volume":"162","author":"Farris","year":"2005","journal-title":"Am J Epidemiol"},{"key":"22","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1055-9965.EPI-09-0472","article-title":"Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial","volume":"18","author":"Kristal","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"23","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ejheart.2007.08.004","article-title":"Mechanistic insight into the functional and toxic effects of Strophanthidin in the failing human myocardium","volume":"9","author":"Pieske","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"24","first-page":"591","article-title":"Anatomophysiologic basis of tetralogy of Fallot and its clinical implications","volume":"29","author":"Leite-Moreira","year":"2010","journal-title":"Rev Port Cardiol"},{"key":"25","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/hrt.2010.203190","article-title":"Impact of restrictive physiology on intrinsic diastolic right ventricular function and lusitropy in children and adolescents after repair of tetralogy of Fallot","volume":"96","author":"Hofbeck","year":"2010","journal-title":"Heart"},{"key":"26","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.yjmcc.2011.02.008","article-title":"Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity","volume":"50","author":"Zaza","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10557-011-6283-y","article-title":"Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters","volume":"25","author":"Borsini","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCRESAHA.113.300895","article-title":"Intracellular dyssynchrony of diastolic cytosolic [Ca(2)(+)] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure","volume":"113","author":"Heinzel","year":"2013","journal-title":"Circ Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00246-005-1186-y","article-title":"Right ventricular diastolic function after repair of tetralogy of Fallot","volume":"27","author":"Kumar","year":"2006","journal-title":"Pediatr Cardiol"},{"key":"30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ejheart.2008.07.007","article-title":"Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent","volume":"10","author":"Carminati","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MJT.0b013e31816d9186","article-title":"Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial","volume":"15","author":"Gheorghiade","year":"2008","journal-title":"Am J Ther"},{"key":"32","doi-asserted-by":"publisher","first-page":"47A","DOI":"10.1016\/j.amjcard.2006.09.006","article-title":"A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function","volume":"99","author":"Gheorghiade","year":"2007","journal-title":"Am J Cardiol"},{"key":"33","doi-asserted-by":"publisher","first-page":"24A","DOI":"10.1016\/j.amjcard.2006.09.003","article-title":"Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure","volume":"99","author":"Bianchi","year":"2007","journal-title":"Am J Cardiol"},{"key":"34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/187152909789007070","article-title":"Investigational positive inotropic agents for acute heart failure","volume":"9","author":"Delpon","year":"2009","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11936-010-0090-9","article-title":"Inotropic therapy for end-stage heart failure patients","volume":"12","author":"Starling","year":"2010","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Nihoyannopoulos","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jacc.2005.02.091","article-title":"Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis","volume":"46","author":"Gheorghiade","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cardfail.2003.12.005","article-title":"Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis","volume":"10","author":"McMurray","year":"2004","journal-title":"J Card Fail"},{"key":"39","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/eurheartj\/ehv143","article-title":"Digoxin-associated mortality: a systematic review and meta-analysis of the literature","volume":"36","author":"Hohnloser","year":"2015","journal-title":"Eur Heart J"},{"key":"40","doi-asserted-by":"publisher","first-page":"h4451","DOI":"10.1136\/bmj.h4451","article-title":"Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data","volume":"351","author":"Kotecha","year":"2015","journal-title":"BMJ"},{"key":"41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Young","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.amjmed.2012.10.022","article-title":"Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction","volume":"126","author":"Go","year":"2013","journal-title":"Am J Med"},{"key":"43","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community","volume":"296","author":"Roger","year":"2006","journal-title":"JAMA"},{"key":"44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Redfield","year":"2006","journal-title":"N Engl J Med"},{"key":"45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/bph.12278","article-title":"Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition","volume":"169","author":"Ferrari","year":"2013","journal-title":"Br J Pharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T20:56:02Z","timestamp":1589144162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,30]]},"references-count":45,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2017,7,25]]}},"alternative-id":["17540","28514771"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17540","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,30]]}}}